FDMT

Business Context and Reporting Period

Company: 4D Molecular Therapeutics, Inc. (FDMT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: 4DMT is a clinical-stage biotechnology company developing genetic medicines using its proprietary Therapeutic Vector Evolution (TVE) platform. The company focuses on two core therapeutic areas: ophthalmology (wet AMD and DME) and pulmonology (cystic fibrosis). In January 2025, the company implemented a strategic pipeline prioritization, terminating development of 4D-110 and 4D-125 and seeking strategic alternatives for 4D-175, 4D-725, and 4D-310.

Key Financial Metrics

Note: Revenue consists primarily of collaboration and license fees. The company has no product sales revenue.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased by approximately 100% to $37,000 in 2024 compared to $20.7 million in 2023. This was primarily due to the recognition of a $20 million upfront payment from Astellas Gene Therapies in 2023, which did not recur in 2024.
• Increased Operating Loss: Net loss increased by 60% to $160.9 million, driven by a 46% increase in R&D expenses ($44.2 million increase) and a 28% increase in G&A expenses ($10.1 million increase).
• R&D Expense Drivers: The increase in R&D was attributed to higher clinical trial activity for lead candidate 4D-150, increased headcount, and higher stock-based compensation.
• Liquidity Position: Cash and marketable securities increased significantly to $505.5 million as of December 31, 2024, following a February 2024 public offering that raised approximately $316 million in net proceeds.

Guidance, Outlook, and Risks

Clinical Pipeline Updates

• 4D-150 (Ophthalmology): Positive interim data reported for wet AMD (PRISM trial) and DME (SPECTRA trial). The company plans to initiate two Phase 3 trials (4FRONT-1 and 4FRONT-2) in 2025, with topline data expected in the second half of 2027.
• 4D-710 (Pulmonology): Positive interim data from the AEROW Phase 1/2 trial in cystic fibrosis demonstrated successful delivery and expression of the CFTR transgene. The company is continuing enrollment.

Outlook and Capital Requirements

Management believes existing cash resources ($505.5 million) are sufficient to fund planned operations for at least one year from the filing date. The company expects to continue incurring significant operating losses as it advances clinical trials and scales manufacturing. Future funding will likely be required through equity offerings, debt, or strategic collaborations.

Key Risks

• Development Risk: Failure of clinical trials to demonstrate safety or efficacy, particularly in the upcoming Phase 3 studies for 4D-150.
• Regulatory Risk: Uncertainty regarding regulatory approval pathways for novel AAV genetic medicines.
• Capital Risk: Dependence on raising additional capital to fund operations; potential dilution to shareholders.
• Manufacturing Risk: Complexity of manufacturing AAV vectors and reliance on third-party suppliers for certain raw materials.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $505.5 million cash balance against the projected burn rate for the upcoming Phase 3 trials.
• Phase 3 Trial Design: Review the specific endpoints and comparator arms for the 4FRONT-1 and 4FRONT-2 trials to assess the probability of non-inferiority against aflibercept.
• Revenue Sustainability: Confirm the timeline for future milestone payments from collaboration partners (Astellas, CFF) given the lack of product revenue.
• Dilution Impact: Assess the impact of outstanding pre-funded warrants (approx. 9.9 million shares) and options on future earnings per share.
• Manufacturing Capacity: Evaluate the status of internal cGMP manufacturing capabilities versus reliance on CMOs for Phase 3 supply.